The DOI matches its Crossref record; 401 of the 401 references it cites were found in a registry or an index.
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Open accessAbstract
Polymeric materials have been used in a range of pharmaceutical and biotechnology products for more than 40 years. These materials have evolved from their earlier use as biodegradable products such as resorbable sutures, orthopaedic implants, macroscale and microscale drug delivery systems such as microparticles and wafers used as controlled drug release depots, to multifunctional nanoparticles (NPs) capable of targeting, and controlled release of therapeutic and diagnostic agents. These newer generations of targeted and controlled release polymeric NPs are now engineered to navigate the complex in vivo environment, and incorporate functionalities for achieving target specificity, control of drug concentration and exposure kinetics at the tissue, cell, and subcellular levels. Indeed this optimization of drug pharmacology as aided by careful design of multifunctional NPs can lead to improved drug safety and efficacy, and may be complimentary to drug enhancements that are traditionally achieved by medicinal chemistry. In this regard, polymeric NPs have the potential to result in a highly differentiated new class of therapeutics, distinct from the original active drugs used in their composition, and distinct from first generation NPs that largely facilitated drug formulation. A greater flexibility in the design of drug molecules themselves may also be facilitated following their incorporation into NPs, as drug properties (solubility, metabolism, plasma binding, biodistribution, target tissue accumulation) will no longer be constrained to the same extent by drug chemical composition, but also become in-part the function of the physicochemical properties of the NP. The combination of optimally designed drugs with optimally engineered polymeric NPs opens up the possibility of improved clinical outcomes that may not be achievable with the administration of drugs in their conventional form. In this critical review, we aim to provide insights into the design and development of targeted polymeric NPs and to highlight the challenges associated with the engineering of this novel class of therapeutics, including considerations of NP design optimization, development and biophysicochemical properties. Additionally, we highlight some recent examples from the literature, which demonstrate current trends and novel concepts in both the design and utility of targeted polymeric NPs (444 references).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,812
The origins and the future of microfluidics
Whitesides, G. M. (2006) · Nature · doi:10.1038/nature05058 · Cited by 9,687
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Self-citationUnderstanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Cited by
Items 101–130 of 130
Recent trends in the design of anticancer polymer prodrug nanocarriers
Delplace, V., Couvreur, P., & Nicolas, J. (2014) · Polym. Chem. · doi:10.1039/c3py01384g · Cited by 287
Zhong, Y., Zhang, J., Cheng, R., Deng, C., Meng, F., Xie, F., & Zhong, Z. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.012 · Cited by 286
Recent advances in the formulation of PLGA microparticles for controlled drug delivery
Lagreca, E., Onesto, V., Di Natale, C., La Manna, S., Netti, P. A., & Vecchione, R. (2020) · Progress in Biomaterials · doi:10.1007/s40204-020-00139-y · Cited by 284
Engineered nanomedicine for myeloma and bone microenvironment targeting
Swami, A., Reagan, M. R., Basto, P., Mishima, Y., Kamaly, N., Glavey, S., Zhang, S., Moschetta, M., Seevaratnam, D., Zhang, Y., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401337111 · Cited by 283
Self-citationSong, X., Wang, X., Yu, S., Cao, J., Li, S., Li, J., Liu, G., Yang, H., & Chen, X. (2015) · Advanced Materials · doi:10.1002/adma.201405634 · Cited by 279
Zhang, Q., Wang, X., Li, P., Nguyen, K. T., Wang, X., Luo, Z., Zhang, H., Tan, N. S., & Zhao, Y. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201302988 · Cited by 276
Recent applications of immunomodulatory biomaterials for disease immunotherapy
Dai, H., Fan, Q., & Wang, C. (2022) · Exploration · doi:10.1002/exp.20210157 · Cited by 268
Werner, M. E., Cummings, N. D., Sethi, M., Wang, E. C., Sukumar, R., Moore, D. T., & Wang, A. Z. (2013) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2013.02.009 · Cited by 267
Ali, E. S., Sharker, S. M., Islam, M. T., Khan, I. N., Shaw, S., Rahman, M. A., Uddin, S. J., Shill, M. C., Rehman, S., Das, N., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.011 · Cited by 267
Inorganic nanomaterials for bioimaging, targeted drug delivery and therapeutics
Liang, R., Wei, M., Evans, D. G., & Duan, X. (2014) · Chem. Commun. · doi:10.1039/c4cc03118k · Cited by 262
Lipid based nanocarriers: a translational perspective
Mishra, D. K., Shandilya, R., & Mishra, P. K. (2018) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2018.05.021 · Cited by 258
Wang, Y., Li, P., Truong-Dinh Tran, T., Zhang, J., & Kong, L. (2016) · Nanomaterials · doi:10.3390/nano6020026 · Cited by 255
Enzyme-Responsive Nanoparticles for Anti-tumor Drug Delivery
Li, M., Zhao, G., Su, W.-K., & Shuai, Q. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00647 · Cited by 253
Priya, S., Desai, V. M., & Singhvi, G. (2023) · ACS Omega · doi:10.1021/acsomega.2c05976 · Cited by 228
Abd Ellah, N. H., & Abouelmagd, S. A. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1213238 · Cited by 164
Xiao, B., Han, M. K., Viennois, E., Wang, L., Zhang, M., Si, X., & Merlin, D. (2015) · Nanoscale · doi:10.1039/c5nr04831a · Cited by 152
PEGylated nanomedicines: recent progress and remaining concerns
Vllasaliu, D., Fowler, R., & Stolnik, S. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.866651 · Cited by 137
Ta, H. T., Truong, N. P., Whittaker, A. K., Davis, T. P., & Peter, K. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1316262 · Cited by 105
Gaspar, V. M., Gonçalves, C., de Melo-Diogo, D., Costa, E. C., Queiroz, J. A., Pichon, C., Sousa, F., & Correia, I. J. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.040 · Cited by 91
Pöppler, A., Lübtow, M. M., Schlauersbach, J., Wiest, J., Meinel, L., & Luxenhofer, R. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201908914 · Cited by 72
Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges
Ubanako, P., Mirza, S., Ruff, P., & Penny, C. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1447953 · Cited by 68
Enzyme-responsive protein/polysaccharide supramolecular nanoparticles
Hou, X.-F., Chen, Y., & Liu, Y. (2015) · Soft Matter · doi:10.1039/c4sm02896a · Cited by 65
Triptolide delivery: Nanotechnology-based carrier systems to enhance efficacy and limit toxicity
Ren, Q., Li, M., Deng, Y., Lu, A., & Lu, J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105377 · Cited by 64
Banerjee, S. R., Foss, C. A., Horhota, A., Pullambhatla, M., McDonnell, K., Zale, S., & Pomper, M. G. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.6b01485 · Cited by 54
Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging
Park, J., Kim, S., Saw, P. E., Lee, I.-H., Yu, M. K., Kim, M., Lee, K., Kim, Y.-C., Jeong, Y. Y., & Jon, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.08.029 · Cited by 48
Li, H., Li, J., Ke, W., & Ge, Z. (2015) · Macromolecular Rapid Communications · doi:10.1002/marc.201500337 · Cited by 47
Ma, X., Chen, X., Yi, Z., Deng, Z., Su, W., Chen, G., Ma, L., Ran, Y., Tong, Q., & Li, X. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c04698 · Cited by 36
Souri, M., Elahi, S., & Soltani, M. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2323211 · Cited by 28
Liu, Y., Fens, M. H. A. M., Capomaccio, R. B., Mehn, D., Scrivano, L., Kok, R. J., Oliveira, S., Hennink, W. E., & van Nostrum, C. F. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.10.040 · Cited by 25
In situ measurements of polymer micellization kinetics with millisecond temporal resolution
Kalkowski, J., Liu, C., Leon-Plata, P., Szymusiak, M., Zhang, P., Irving, T., Shang, W., Bilsel, O., & Liu, Y. (2019) · Macromolecules · doi:10.1021/acs.macromol.8b02257 · Cited by 23
Metadata
- Authors
- Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2012
- Volume
- 41
- Issue
- 7
- Pages
- 2971
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W2127410754
- Cited by
- 1,730
- References
- 401
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.